Showing 2771-2780 of 2985 results for "".
- New Technical Manager at Jurliquehttps://practicaldermatology.com/news/20130531-new_technical_manager_at_jurlique/2459527/Jurlique appointed Connie Lim to Technical Manager of Global Product Development. In her new role, Ms. Lim will drive innovative formula development, provide technical support, and monitor performance and key milestones in global new product development efforts. Ms. Lim comes to Jurlique with mor
- Two Melanoma Drugs Win FDA Approvalhttps://practicaldermatology.com/news/20130530-two_melanoma_drugs_win_fda_approval/2459528/The FDA approved two new drugs for metastatic or inoperable melanoma, dabrafenib (Tafinlar) and trametinib (Mekinist). Dabrafenib is an inhibitor of the BRAF gene when it carries the so-called V600E mutation. Trametinib inhibits a target known as MEK and is effective primarily against melanomas carr
- Actavis to Acquire Warner Chilcotthttps://practicaldermatology.com/news/20130521-actavis_to_acquire_warner_chilcott/2459533/Actavis will acquire Warner Chilcott plc in a stock-for-stock transaction valued at approximately $8.5 billion. If successfully completed, the transaction will create a global specialty pharmaceutical company with approximately $11 billion in combined annual revenue, and the third-largest US special
- Clark Pharmaceuticals, Ferndale Healthcare Launch DerMendhttps://practicaldermatology.com/news/20130521-clark_pharmaceuticals_ferndale_healthcare_launch_dermend/2459534/Clark Pharmaceuticals partnered with Ferndale Healthcare to launch DerMend Moisturizing Bruise Formula. The formula is predicated on the idea that skin over 50 tends to get thinner and bruises more easily. Blood thinners, even those like low-dose baby aspirin, can cause skin to bruise. DerMend is de
- Skinceuticals Uses Viral Video to Raise Skin Cancer Awarenesshttps://practicaldermatology.com/news/20130516-skinceuticals_uses_viral_video_to_raise_skin_cancer_awareness/2459541/In honor of Skin Cancer Awareness Month, SkinCeuticals will be sponsoring free, full body skin cancer checks at select dermatologist offices across the country. To encourage consumers to get their skin checked before the summer season, SkinCeuticals created a digital video "spot," cast with celebrit
- JUVÉDERM VOLUMA™ XC Receives Unanimous Recommendation from FDA Panelhttps://practicaldermatology.com/news/20130514-juvderm_voluma_xc_receives_unanimous_recommendation_from_fda/2459545/The US Food and Drug Administration General and Plastic Surgery Devices Panel of the Medical Devices Advisory Committee voted unanimously that the benefits of JUVÉDERM VOLUMA™ XC, an injectable hyaluronic acid dermal filler for cheek augme
- Free Skin Health Screenings This Weekendhttps://practicaldermatology.com/news/20130510-free_skin_health_screenings_this_weekend/2459549/In the interest of Skin Cancer Awareness Month, Sam's Clubs nationwide are offering free skin health screenings on Saturday, May 11 from 11am-3pm to members and non members. Those screened are being encouraged to take results to a dermatologist to get proper treatment and advice after their exams. T
- OXY Unveils Overhauled Acne Lineshttps://practicaldermatology.com/news/20130507-oxy_unveils_overhauled_acne_lines/2459550/After 30 years, the OXY brand (Mentholatum Company) has had a makeover and now offers two distinct lines grouped by active ingredients designed to either kill acne (benzoyl peroxide) or provide maintenance for acne-prone skin (salicylic acid). The OXY Maximum Action line includes, among others, OXY
- Pliaglis Launches in Europehttps://practicaldermatology.com/news/20130502-pliaglis_launches_in_europe/2459551/Nuvo Research Inc. and Galderma Pharma, S.A. launched Pliaglis (lidocaine and tetracaine) Cream 7%/7% in Europe. Nuvo has licensed worldwide marketing rights for Pliaglis to Galderma, and licenses have been issued in 14 of the 16 European cou
- Ipsen's Dysport Approved for Use in Canadahttps://practicaldermatology.com/news/20130418-ipsens_dysport_approved_for_use_in_canada/2459560/Health Canada granted a marketing authorization for Dysport (Botulinum toxin type A for injection) for the temporary improvement in the appearance of moderate to severe frown lines (glabellar lines) in adult patients younger than 65 years of age. Medicis Aesthetics Canada, a division of Valeant Phar